Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR, where she has reported on accelerated drug approvals whose confirmatory trials were overdue, Operation Warp Speed contract accountability, and the ripple effects of obesity drug shortages.
Before coming to NPR, she was a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress.
Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award, and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
She can be reached via encrypted message at sydneylupkin.36 on Signal.
-
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry. -
TrumpRx, the administration's discounted drug website, has been online for nearly six months. How useful is it, and how much has it changed what Americans pay for prescriptions?
-
Medicare is offering beneficiaries access to popular obesity drugs for a $50 monthly copay. Patients have to meet certain criteria to qualify. It's a temporary measure that runs through 2027.
-
If your doctor prescribes a GLP-1 medication for weight loss but your insurance won't cover it, you have options.
